Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00050349 · ClinicalTrials.gov registry record · Phase 2
EPO906 in Carcinoid and Other Neuroendocrine Tumors
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT00050349 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 33 participants.
The verdict
NCT00050349, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause metastatic carcinoid and other neuroendocrine tumors.
Interventions
- DRUG EPO906 epothilone B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2002-07 |
| Est. Completion | 2007-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00050349
The ClinicalTrials.gov registry entry for NCT00050349 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EPO906 epothilone B is the first listed.
NCT00050349 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00050349 about?
NCT00050349 is a clinical study titled "EPO906 in Carcinoid and Other Neuroendocrine Tumors". This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause metastatic carcinoid and other neuroendocrine tumors.
What is the current status of trial NCT00050349?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2002-07. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00050349?
The interventions under investigation include: EPO906 epothilone B (DRUG).
Who is sponsoring clinical trial NCT00050349?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.